The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, A. D.
Right arrow Articles by Shields, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinberg, A. D.
Right arrow Articles by Shields, J.
The Journal of Immunology, 2000, 164: 2160-2169.
Copyright © 2000 by The American Association of Immunologists

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1

Andrew D. Weinberg2,*, Martin-Muy Rivera*, Rodney Prell*, Arden Morris{dagger}, Trygg Ramstad*, John T. Vetto{dagger}, Walter J. Urba*, Gregory Alvord§, Campbell Bunce{ddagger} and John Shields{ddagger}

* Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213; {dagger} Department of Surgery, Section of Surgical Oncology, Oregon Health Science University, Portland, OR 97201; {ddagger} Cantab Pharmaceuticals, Cambridge, United Kingdom; and § Computer and Statistical Services, National Cancer Institute-Frederick Research and Development Center, Frederick, MD 21702

The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor-specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20–55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host’s tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.




This article has been cited by other articles:


Home page
BloodHome page
A. M. Keller, Y. Xiao, V. Peperzak, S. H. Naik, and J. Borst
Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
Blood, May 21, 2009; 113(21): 5167 - 5175.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med., May 11, 2009; 206(5): 1103 - 1116.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Houot and R. Levy
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Blood, April 9, 2009; 113(15): 3546 - 3552.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Krause, M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler
Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells
Blood, March 12, 2009; 113(11): 2451 - 2460.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. E. Ruby and A. D. Weinberg
OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age
J. Immunol., February 1, 2009; 182(3): 1481 - 1489.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Cancer Res., July 1, 2008; 68(13): 5206 - 5215.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Piconese, B. Valzasina, and M. P. Colombo
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
J. Exp. Med., April 14, 2008; 205(4): 825 - 839.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. E. Ruby, R. Montler, R. Zheng, S. Shu, and A. D. Weinberg
IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival
J. Immunol., February 15, 2008; 180(4): 2140 - 2148.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. L. Redmond, M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg
Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist
J. Immunol., December 1, 2007; 179(11): 7244 - 7253.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. A. Williams, S. E. Murray, A. D. Weinberg, and D. C. Parker
OX40-Mediated Differentiation to Effector Function Requires IL-2 Receptor Signaling but Not CD28, CD40, IL-12Rbeta2, or T-bet
J. Immunol., June 15, 2007; 178(12): 7694 - 7702.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. H. Thompson, H. Dong, and E. D. Kwon
Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
Clin. Cancer Res., January 15, 2007; 13(2): 709s - 715s.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Y. Usui, Y. Okunuki, T. Hattori, M. Takeuchi, T. Kezuka, H. Goto, and M. Usui
Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4607 - 4613.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Q. Yu, F. Y. Yue, X. X. Gu, H. Schwartz, C. M. Kovacs, and M. A. Ostrowski
OX40 Ligation of CD4+ T Cells Enhances Virus-Specific CD8+ T Cell Memory Responses Independently of IL-2 and CD4+ T Regulatory Cell Inhibition
J. Immunol., February 15, 2006; 176(4): 2486 - 2495.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Murata, B. H. Ladle, P. S. Kim, E. R. Lutz, M. E. Wolpoe, S. E. Ivie, H. M. Smith, T. D. Armstrong, L. A. Emens, E. M. Jaffee, et al.
OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen
J. Immunol., January 15, 2006; 176(2): 974 - 983.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Song, X. Tang, K. M. Harms, and M. Croft
OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen
J. Immunol., September 15, 2005; 175(6): 3534 - 3541.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Dannull, S. Nair, Z. Su, D. Boczkowski, C. DeBeck, B. Yang, E. Gilboa, and J. Vieweg
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand
Blood, April 15, 2005; 105(8): 3206 - 3213.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Valzasina, C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. Colombo
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR
Blood, April 1, 2005; 105(7): 2845 - 2851.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Lustgarten, A. L. Dominguez, and M. Thoman
Aged Mice Develop Protective Antitumor Immune Responses with Appropriate Costimulation
J. Immunol., October 1, 2004; 173(7): 4510 - 4515.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Zingoni, T. Sornasse, B. G. Cocks, Y. Tanaka, A. Santoni, and L. L. Lanier
Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions
J. Immunol., September 15, 2004; 173(6): 3716 - 3724.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. D. Weinberg, D. E. Evans, C. Thalhofer, T. Shi, and R. A. Prell
The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement
J. Leukoc. Biol., June 1, 2004; 75(6): 962 - 972.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. K. Lathrop, C. A. Huddleston, P. A. Dullforce, M. J. Montfort, A. D. Weinberg, and D. C. Parker
A Signal through OX40 (CD134) Allows Anergic, Autoreactive T Cells to Acquire Effector Cell Functions
J. Immunol., June 1, 2004; 172(11): 6735 - 6743.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Andarini, T. Kikuchi, M. Nukiwa, P. Pradono, T. Suzuki, S. Ohkouchi, A. Inoue, M. Maemondo, N. Ishii, Y. Saijo, et al.
Adenovirus Vector-Mediated in Vivo Gene Transfer of OX40 Ligand to Tumor Cells Enhances Antitumor Immunity of Tumor-Bearing Hosts
Cancer Res., May 1, 2004; 64(9): 3281 - 3287.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. M. Finney, A. N. Akbar, and A. D. G. Lawson
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain
J. Immunol., January 1, 2004; 172(1): 104 - 113.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Martin-Orozco, Z. Chen, L. Poirot, E. Hyatt, A. Chen, O. Kanagawa, A. Sharpe, D. Mathis, and C. Benoist
Paradoxical Dampening of Anti-Islet Self-Reactivity but Promotion of Diabetes by OX40 Ligand
J. Immunol., December 15, 2003; 171(12): 6954 - 6960.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. R. Humphreys, L. Edwards, G. Walzl, A. J. Rae, G. Dougan, S. Hill, and T. Hussell
OX40 Ligation on Activated T Cells Enhances the Control of Cryptococcus neoformans and Reduces Pulmonary Eosinophilia
J. Immunol., June 15, 2003; 170(12): 6125 - 6132.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. R. Blazar, A. H. Sharpe, A. I. Chen, A. Panoskaltsis-Mortari, C. Lees, H. Akiba, H. Yagita, N. Killeen, and P. A. Taylor
Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients
Blood, May 1, 2003; 101(9): 3741 - 3748.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Gri, E. Gallo, E. Di Carlo, P. Musiani, and M. P. Colombo
OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response
J. Immunol., January 1, 2003; 170(1): 99 - 106.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Dechant, G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. J. van de Winkel, and T. Valerius
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Blood, December 15, 2002; 100(13): 4574 - 4580.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. W. Chan, C. D. Hopke, S. M. Krams, and O. M. Martinez
CD30 Expression Identifies the Predominant Proliferating T Lymphocyte Population in Human Alloimmune Responses
J. Immunol., August 15, 2002; 169(4): 1784 - 1791.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. De Smedt, J. Smith, P. Baum, W. Fanslow, E. Butz, and C. Maliszewski
Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cells In Vivo
J. Immunol., January 15, 2002; 168(2): 661 - 670.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. E. Evans, R. A. Prell, C. J. Thalhofer, A. A. Hurwitz, and A. D. Weinberg
Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of {alpha}OX-40 with {alpha}CTLA-4
J. Immunol., December 15, 2001; 167(12): 6804 - 6811.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor
J. Immunol., December 1, 2001; 167(11): 6669 - 6677.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. C. Ndhlovu, N. Ishii, K. Murata, T. Sato, and K. Sugamura
Critical Involvement of OX40 Ligand Signals in the T Cell Priming Events During Experimental Autoimmune Encephalomyelitis
J. Immunol., September 1, 2001; 167(5): 2991 - 2999.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Kjærgaard, J. Tanaka, J. A. Kim, K. Rothchild, A. Weinberg, and S. Shu
Therapeutic Efficacy of OX-40 Receptor Antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth
Cancer Res., October 1, 2000; 60(19): 5514 - 5521.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.